Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

被引：0

作者：

Pier Paolo M. Berton Giachetti

Giuseppe Curigliano

机构：

[1] Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS),Division of Early Drug Development for Innovative Therapy, European Institute of Oncology

[2] University of Milan,Department of Oncology and Hemato

来源：

Nature Reviews Clinical Oncology | 2024年 / 21卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.

引用

页码：171 / 172

页数：1

共 50 条

[41] New Option for HER2-positive Breast Cancer. First Trastuzumab Biosimilar available
Eiden, Petra
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (7-8) : 485 - 485
[42] Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial
Extra, J. M.
Cognetti, F.
Maraninch, D.
Snyder, R.
Mauriac, L.
Tubiana-Hulin, M.
Chan, S.
Grimes, D.
Anton, A.
Marty, M.
EJC SUPPLEMENTS, 2004, 2 (03): : 125 - 126
[43] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
Farhat, F.
Kattan, J.
Chahine, G.
Makdessi, J.
Bitar, N.
Ghosn, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
[44] Economic impact of adding capecitabine (X) to docetaxel (T) and trastuzumab (H) as first-line therapy for HER2-positive advanced or metastatic breast cancer
Bonettil, A.
Santoro, A.
Ducournau, R.
Cirrincione, A.
Giuliani, G.
Bell, R.
EJC SUPPLEMENTS, 2007, 5 (04): : 224 - 224
[45] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
Onder Tonyali
Mustafa Benekli
Veli Berk
Ugur Coskun
Metin Ozkan
Ramazan Yildiz
Emel Ucgul
Alper Sevinc
Dogan Uncu
Umut Demirci
Suleyman Buyukberber
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
[46] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
Tonyali, Onder
Benekli, Mustafa
Berk, Veli
Coskun, Ugur
Ozkan, Metin
Yildiz, Ramazan
Ucgul, Emel
Sevinc, Alper
Uncu, Dogan
Demirci, Umut
Buyukberber, Suleyman
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
[47] New Option for HER2-positive Breast Cancer First Trastuzumab-Biosimilar available
Eiden, Petra
BREAST CARE, 2018, 13 (03) : 221 - 221
[48] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
Wang, Hao
Wang, Ye
Gong, Ruixue
Geng, Yuyu
Li, Li
ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
[49] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
Nigel Fleeman
Adrian Bagust
Sophie Beale
Kerry Dwan
Rumona Dickson
Chris Proudlove
Yenal Dundar
PharmacoEconomics, 2015, 33 : 13 - 23
[50] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
Fleeman, Nigel
Bagust, Adrian
Beale, Sophie
Dwan, Kerry
Dickson, Rumona
Proudlove, Chris
Dundar, Yenal
PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23

← 1 2 3 4 5 →